LON:AREC Arecor Therapeutics (AREC) Share Price, News & Analysis GBX 42.33 -5.67 (-11.81%) As of 03/28/2025 12:16 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesBuy This Stock About Arecor Therapeutics Stock (LON:AREC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arecor Therapeutics alerts:Sign Up Key Stats Today's Range 42.33▼ 4850-Day Range 42.33▼ 58.9852-Week Range 42.33▼ 170Volume29,002 shsAverage Volume14,676 shsMarket Capitalization£15.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewArecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com Read More… Remove Ads Receive AREC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arecor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AREC Stock News HeadlinesArecor Therapeutics strikes deal for development of peptide therapyMarch 12, 2025 | lse.co.ukArecor Partners to Innovate Peptide Therapy FormulationMarch 12, 2025 | tipranks.comTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 30, 2025 | Porter & Company (Ad)Arecor Full Year 2024 Trading UpdateFebruary 4, 2025 | lse.co.ukArecor Therapeutics confident for the future as revenue risesFebruary 3, 2025 | lse.co.ukArecor Therapeutics Shifts Strategy, Ceases Tetris Pharma OperationsJanuary 10, 2025 | tipranks.comMARKET REPORT: British blue chips set to end the year on a whimperDecember 31, 2024 | msn.comArecor inks licensing deal for AT351December 30, 2024 | uk.investing.comSee More Headlines AREC Stock Analysis - Frequently Asked Questions How have AREC shares performed this year? Arecor Therapeutics' stock was trading at GBX 73.75 at the beginning of the year. Since then, AREC shares have decreased by 42.6% and is now trading at GBX 42.33. View the best growth stocks for 2025 here. How do I buy shares of Arecor Therapeutics? Shares of AREC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Arecor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arecor Therapeutics investors own include Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Lowe's Companies (LOW) and SNDL (SNDL). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryCoal Current SymbolLON:AREC CIKN/A Webwww.americanresourcescorp.com Phone44 1223 426 060FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (28.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-10,683,346.07 Net Margins-176.89% Pretax MarginN/A Return on Equity-118.67% Return on Assets-37.31% Debt Debt-to-Equity Ratio5.51 Current Ratio1.37 Quick Ratio6.24 Sales & Book Value Annual Sales£6.04 million Price / Sales2.65 Cash FlowGBX 8.35 per share Price / Cash Flow5.07 Book ValueGBX 16.58 per share Price / Book2.55Miscellaneous Outstanding Shares37,756,599Free FloatN/AMarket Cap£15.98 million OptionableNot Optionable Beta-0.18 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (LON:AREC) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.